Showing 2221-2230 of 9343 results for "".
- AAD: Half of Americans Aren't Protecting Themselves from the Sunhttps://practicaldermatology.com/news/aad-half-of-americans-arent-protecting-themselves-from-the-sun/2460018/Most Americans aren’t using sun protection as often as they should be —increasing their risk for skin cancer, including melanoma. In fact, just half of Americans always or almost always protect themselves from the sun when they’re outside, according to a new survey by the American Academy of Derma…
- Five-Year Retrospective Study Shows 98.9 Percent Cure Rate for NMSC Patients Treated with Superficial Radiation Therapyhttps://practicaldermatology.com/news/five-year-retrospective-study-shows-989-percent-cure-rate-for-nmsc-patients-treated-with-superficial-radiation-therapy/2460013/Sensus Healthcare, Inc. shared topline results from a five-year retrospective study of non-melanoma skin cancer (NMSC) patients treated with Superficial Radiation Therapy (SRT). The study, which was conducted across four U.S. sites, showed a 98.9 percent cure rate among 516 male and female patients…
- Xstrahl Introduces UpGraded Treatment System for Non-Melanoma Skin Cancerhttps://practicaldermatology.com/news/xstrahl-introduces-upgraded-treatment-system-for-non-melanoma-skin-cancer/2460011/Xstrahl Medical is launching its latest superficial radiotherapy treatment system to treat the full range of non-melanoma skin cancer cases. The new Xstrahl 150 system offers several features that enhance the capabilities of Xstrahl's current 150kV superficial system, including built-in dosimetry…
- FDA Approves AbbVie's Skyrizi for Psoriasishttps://practicaldermatology.com/news/fda-approves-abbvies-skyrizi-for-psoriasis/2460007/Skyrizi™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In clinical trials, Skyrizi produced high rates of durable skin clearance with 8…
- L'Oreal To Support Reconstruction of Notre Dame Cathedralhttps://practicaldermatology.com/news/loreal-to-support-reconstruction-of-notre-dame-cathedral/2460003/The Bettencourt Meyers family and the L’Oréal Group are making a joint donation of 100 million euros toward the “renaissance” of the Notre-Dame Cathedral, which they describe as a symbol of French heritage and common history. The L’Oréal group will also support fundraising among its 86,000 employ…
- Industry Vet Linda Esposito Named New CFO at Skyn ICELANDhttps://practicaldermatology.com/news/industry-vet-linda-esposito-named-new-cfo-at-skyn-iceland/2460002/Linda Esposito is the new Chief Financial Officer at Skyn ICELAND, a privately held New York-based skin care company. Ms. Esposito will report to Founder and Chief Executive Officer Sarah Kugelman and will oversee all financial aspects of the Company. "On behalf of Skyn ICELAND, I am very pleased…
- Maine Gets SUNucatedhttps://practicaldermatology.com/news/maine-gets-sunucated/2460001/Maine is joining 19 other states in allowing students to possess and use sunscreen in school. Governor Janet Mills signed LD 441, which was sponsored by Senator Cathy Breen. Modeled after American Society for Dermatologic Surgery Association’s (ASDSA) SUNucate legislation, the bill was designed to…
- InMode Launches AccuTite, the Smallest RFAL Treatment for Face and Bodyhttps://practicaldermatology.com/news/inmode-launches-accutite-the-smallest-rfal-treatment-for-face-and-body/2460000/InMode Ltd. is introducing AccuTite, the smallest Radio-Frequency Assisted Lipolysis (RFAL) device for precision fat reduction or skin contraction in the face and body. With its sub-millimeter cannula, AccuTite enables focal RF contraction without excisional surgery. There is little or no visible …
- A Conserved Stress Response May Fuel Resistance to BRAF Inhibitors in Melanomahttps://practicaldermatology.com/news/a-conserved-stress-response-may-fuel-resistance-to-braf-inhibitors-in-melanoma/2459999/Moffitt Cancer Center researchers have discovered a mechanism by which melanoma cells become resistant to drugs that target the BRAF protein and its signaling pathway. Their study was published online in the journal Cancer Research. Mutations in BRAF are found in approximately 50 percent of all …
- American Skin Association Names Almirall Distinguished Corporate Leaderhttps://practicaldermatology.com/news/american-skin-association-names-almirall-distinguished-corporate-leader/2459997/Almirall took home the Distinguished Corporate Leadership award by the American Skin Association (ASA). Ron Menezes, President and General Manager of Almirall LLC, accepted the award and spoke about Almirall's new corporate purpose which aligns with ASA’s mission to advance research, champion sk…